Prognose

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

BioLineRx Ltd. (BLRX) Q4 2024 Earnings Call Transcript
BioLineRx Ltd. (NASDAQ:BLRX ) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Irina Koffler - IR, LifeSci Advisors Phil Serlin - CEO Mali Zeevi - CFO Ella Sorani - Chief Development Officer Conference Call Participants Joe Pantginis - HC Wainwright John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by.» Mehr auf seekingalpha.com
BioLineRx Reports 2024 Financial Results and Provides Corporate Update
- Reports meaningful progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare diseases - - Executed license agreement with Ayrmid Pharma Ltd. for APHEXDA ® (motixafortide) with $10 million upfront payment, up to $87 million in commercial milestones, and high double-digit royalties on net sales - - Completed financings raising combined gross proceeds of $19 million and reduced operating expense run rate by 70%, extending the Company's cash runway through H2 2026 - - Management to host conference call today, March 31 st, at 8:30 am EDT - TEL AVIV, Israel , March 31, 2025 /PRNewswire/ -- BioLineRx Ltd.» Mehr auf prnewswire.com
BioLineRx to Report 2024 Annual Results on March 31, 2025
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , March 24, 2025 /PRNewswire/ -- BioLineRx Ltd.» Mehr auf prnewswire.com

Im letzten Quartal hatte BioLineRx Ltd ADR einen Umsatz von 11,29 Mio€ und ein Nettoeinkommen von −3,06 Mio€